PMID- 38205500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240112
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 12
DP  - 2023 Dec
TI  - Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With 
      Esophageal Cancer.
PG  - e50343
LID - 10.7759/cureus.50343 [doi]
LID - e50343
AB  - Local treatment of oligometastatic esophagogastric cancer has been reported to 
      improve overall survival (OS) compared to systemic therapy alone. This study 
      evaluated the feasibility and safety of proton beam therapy (PBT) for the 
      treatment of lung oligometastatic recurrence in esophageal cancer patients. This 
      single-center historical cohort study enrolled 11 patients who underwent PBT for 
      lung oligometastasis from esophageal cancer between 2010 and 2019. The selection 
      criteria were that the primary esophageal cancer was controlled and no more than 
      three lung metastases without outside lung tumors were present. OS, 
      progression-free survival (PFS), and local control (LC) rates and adverse events 
      (AEs) were assessed. Factors that may be related to OS were also investigated. 
      The median follow-up period was 27.8 months (8.8-141.3 months). The one-, two-, 
      and three-year OS rates were 81.8%, 72.7%, and 51.9%, respectively (median OS 
      time: 43.7 months); PFS rates were 45.5%, 27.3%, and 27.3%, respectively (median 
      PFS time: 8.8 months); and LC rates were 92.3%, 72.7%, and 72.7%, respectively. 
      The eighth edition of tumor-node-metastasis (TNM) classification for esophageal 
      cancer was the only significant OS-related factor (p = 0.0309). No grade >/= 3 AEs 
      were observed. Based on the low incidence of AEs and acceptable LC rate, PBT is a 
      feasible option for the treatment of lung oligometastasis in esophageal cancer 
      patients.
CI  - Copyright (c) 2023, Yamaguchi et al.
FAU - Yamaguchi, Hisashi
AU  - Yamaguchi H
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima, JPN.
FAU - Kato, Takahiro
AU  - Kato T
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
FAU - Honda, Michitaka
AU  - Honda M
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima, JPN.
AD  - Department of Surgery, Southern Tohoku General Hospital, Koriyama, JPN.
FAU - Hamada, Koichi
AU  - Hamada K
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima, JPN.
AD  - Department of Gastroenterology, Southern Tohoku General Hospital, Koriyama, JPN.
FAU - Ishikawa, Yojiro
AU  - Ishikawa Y
AD  - Department of Radiology, Tohoku Medical and Pharmaceutical University, Sendai, 
      JPN.
FAU - Seto, Ichiro
AU  - Seto I
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
FAU - Takagawa, Yoshiaki
AU  - Takagawa Y
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
FAU - Suzuki, Motohisa
AU  - Suzuki M
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
FAU - Kikuchi, Yasuhiro
AU  - Kikuchi Y
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
FAU - Murakami, Masao
AU  - Murakami M
AD  - Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 
      Koriyama, JPN.
LA  - eng
PT  - Journal Article
DEP - 20231211
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10781415
OTO - NOTNLM
OT  - esophageal cancer (ec)
OT  - isolated lung metastasis
OT  - oligometastasis
OT  - overall survival (os)
OT  - proton beam therapy
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/01/11 07:43
MHDA- 2024/01/11 07:44
PMCR- 2023/12/11
CRDT- 2024/01/11 04:21
PHST- 2023/12/10 00:00 [accepted]
PHST- 2024/01/11 07:44 [medline]
PHST- 2024/01/11 07:43 [pubmed]
PHST- 2024/01/11 04:21 [entrez]
PHST- 2023/12/11 00:00 [pmc-release]
AID - 10.7759/cureus.50343 [doi]
PST - epublish
SO  - Cureus. 2023 Dec 11;15(12):e50343. doi: 10.7759/cureus.50343. eCollection 2023 
      Dec.